Please use this identifier to cite or link to this item:
Title: Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
Authors: Linda Aurpibul
Pagakrong Lumbiganon
Rawiwan Hansudewechakul
Suparat Kanjanavanit
Torsak Bunupuradah
Pope Kosalaraksa
Pawinee Taeprasert
Thanyawee Puthanakit
Keywords: Medicine
Issue Date: 1-Apr-2017
Abstract: Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.
ISSN: 15320987
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.